EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nabriva Therapeutics's enterprise value is $-1.64 Mil.
Nabriva Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-53.61 Mil. Therefore, Nabriva Therapeutics's EV-to-EBITDA for today is 0.03.
The historical rank and industry rank for Nabriva Therapeutics's EV-to-EBITDA or its related term are showing as below:
NBRVF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.59 Med: -0.07 Max: 0.33
Current: 0.03
During the past 10 years, the highest EV-to-EBITDA of Nabriva Therapeutics was 0.33. The lowest was -1.59. And the median was -0.07.
NBRVF's EV-to-EBITDA is ranked better than 96.76% of 463
companies
in the Biotechnology industry
Industry Median: 9.32
vs NBRVF: 0.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nabriva Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Nabriva Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Nabriva Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's EV-to-EBITDA falls into.
Nabriva Therapeutics's current Enterprise Value is $-1.64 Mil.
Nabriva Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nabriva Therapeutics's PE Ratio for today is calculated as:
Nabriva Therapeutics's share price for today is $0.0001.
Nabriva Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nabriva Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 